1. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder;Winner;Discov. Med.,2013
2. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study;Greden;J. Psychiatr. Res.,2019
3. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment;McMahon;Am. J. Hum. Genet.,2006
4. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: a translational approach;Qesseveur;Neuropharmacology,2016
5. The relationship between the serotonin 2A receptor gene – 1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients;Demirbugen Oz;Hum. Psychopharmacol.,2018